This is an expanded use protocol for patients diagnosed with a Mycobacterium avium complex (MAC). Sponsored by Novartis, the purpose of this program is to make clofazimine available to appropriate patients following clinical presentation.

The Upstate Global Health Institute is currently seeking individuals between 18-75 years of age and have history of Post-Treatment Lyme disease Syndrome (PTLDS). Lyme disease is a public health crisis in the U.S. It is estimated that over 400,000 cases occur every year with 10-20% of those infected going on to develop PTLDS. there are several thoughts as to why these persistent symptoms happen in some people one of them is that there is a persistent infection. Ceftriaxone is an FDA-approved medication recognized as one of the most potent compounds to kill the agent of Lyme disease, but it isn't used often for Lyme Disease outside of the most severe forms because it is given daily for 30 days. However, it has been shown to reduce fatigue and symptoms for 6 months after receiving the drug. This study is looking to see if dosing of Ceftriaxone every 5 days over a period of 6 weeks will be safe, well tolerated and may be more effective than the placebo for subject with PTLDS.

The Upstate Global Health Institute is currently seeking individuals 12+, who recently tested positive for COVID-19, and currently experiencing symptoms of COVID-19 within 5 days. This study is looking at a medication alternative to Paxlovid, and looking for people who are not able to take Paxlovid and considered high risk.

The Upstate Global Health Institute is partnering with Pfizer on a research study to learn more about an investigational vaccine that may help prevent infection caused by Clostridioides difficile (C. difficile). C. difficile is a type of bacteria (germ) that can cause severe diarrhea and gut inflammation. It often affects people who have recently taken antibiotics or spent time in healthcare settings. Currently, no vaccine is approved to prevent C. difficile infection. The Upstate Global Health Institute is seeking individuals 65+ and who have done or more risk factors for  C.difficile infection.